Prognostic Value of Hematological Inflammatory Indices (Platelet-lymphocyte Ratio (PLR), Neutrophil-lymphocyte Ratio (NLR), SII) in Medium and High‐Risk Papillary Thyroid Carcinoma: A Multicenter Cohort Study
Authors' conclusion
Our findings demonstrate that PLR and SII emerged as risk stratification-specific prognostic biomarkers: PLR independently predicted prognosis in intermediate-risk cases, while SII showed superior predictive value for prognosis in high-risk patients. The differential utility of these indices-PLR for intermediate-risk stratification patients and SII for high-risk stratification patients-highlights their complementary roles in clinical decision-making. As routinely available, cost-effective inflammatory markers, PLR and SII may enhance risk-adapted surveillance strategies, though further validation is warranted to standardize cutoff values and integrate them into existing clinical management systems.
Study context
- Population
- Medium and high-risk papillary thyroid carcinoma (PTC) patients from the DTCC study (2014–2016), a multicenter prospective cohort of initial management of differentiated thyroid cancer (DTC) in China
- Participants
- 1,070 PTC patients
- Exposure
- PLR ≤ 115.6 vs higher PLR; SII ≤ 360.9 vs higher SII
- Outcome
- Recurrence and DFS in medium and high-risk PTC
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
- PLR ≤ 115.6: worse disease-free survival (DFS)
- P = 0.001
Observational data: associations, not effects.
Further findings
Recurrence and DFS in high-risk PTC
| Estimate | P value | ||
|---|---|---|---|
| SII ≤ 360.9Recurrence | OR 15.154 (95% CI 1.873–122.640) | P = 0.011 | |
| SII ≤ 360.9Shorter DFS, multivariate analysis | HR 14.399 (95% CI 1.823–113.730) | P = 0.011 | |
| 0.050.21520Ratio (log scale) |
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →